NO973609L - Fremgangsmåte for å inhibere effektene av IL-6 - Google Patents

Fremgangsmåte for å inhibere effektene av IL-6

Info

Publication number
NO973609L
NO973609L NO973609A NO973609A NO973609L NO 973609 L NO973609 L NO 973609L NO 973609 A NO973609 A NO 973609A NO 973609 A NO973609 A NO 973609A NO 973609 L NO973609 L NO 973609L
Authority
NO
Norway
Prior art keywords
inhibiting
effects
hexamethylenimino
piperidino
solvate
Prior art date
Application number
NO973609A
Other languages
English (en)
Norwegian (no)
Other versions
NO973609D0 (no
Inventor
Andrew Lawrence Glasebrook
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO973609D0 publication Critical patent/NO973609D0/no
Publication of NO973609L publication Critical patent/NO973609L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
NO973609A 1995-02-06 1997-08-05 Fremgangsmåte for å inhibere effektene av IL-6 NO973609L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06
PCT/US1996/001621 WO1996024356A1 (fr) 1995-02-06 1996-02-05 Procede d'inhibition des effets d'il-6

Publications (2)

Publication Number Publication Date
NO973609D0 NO973609D0 (no) 1997-08-05
NO973609L true NO973609L (no) 1997-09-11

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973609A NO973609L (no) 1995-02-06 1997-08-05 Fremgangsmåte for å inhibere effektene av IL-6

Country Status (14)

Country Link
EP (1) EP0724879A2 (fr)
JP (1) JPH10513470A (fr)
KR (1) KR19980701933A (fr)
CN (1) CN1173819A (fr)
AU (1) AU708374B2 (fr)
CA (1) CA2212232A1 (fr)
CZ (1) CZ246597A3 (fr)
FI (1) FI973235A0 (fr)
HU (1) HUP9801829A3 (fr)
IL (1) IL117036A0 (fr)
NO (1) NO973609L (fr)
WO (1) WO1996024356A1 (fr)
YU (1) YU6996A (fr)
ZA (1) ZA96897B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
WO1999051587A1 (fr) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
ES2207982T3 (es) * 1998-12-30 2004-06-01 Signal Pharmaceuticals, Inc. Compuestos y metodos para la modulacion de receptores estrogenicos.
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
CN1723013A (zh) * 2003-01-06 2006-01-18 惠氏公司 雌激素受体α调节剂在治疗多发性硬化症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
FI973235A (fi) 1997-08-05
CA2212232A1 (fr) 1996-08-15
AU708374B2 (en) 1999-08-05
AU4916396A (en) 1996-08-27
HUP9801829A2 (hu) 1999-05-28
KR19980701933A (ko) 1998-06-25
NO973609D0 (no) 1997-08-05
FI973235A0 (fi) 1997-08-05
ZA96897B (en) 1997-08-05
HUP9801829A3 (en) 1999-10-28
WO1996024356A1 (fr) 1996-08-15
CN1173819A (zh) 1998-02-18
EP0724879A3 (fr) 1996-09-11
EP0724879A2 (fr) 1996-08-07
IL117036A0 (en) 1996-06-18
JPH10513470A (ja) 1998-12-22
MX9705940A (es) 1997-10-31
CZ246597A3 (cs) 1998-06-17
YU6996A (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO20000750L (no) FremgangsmÕte for Õ redusere blodplatetall
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
NO975561L (no) Kalsiumkanalantagonister
DK0771201T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
NO973470L (no) Fremgangsmåte for minsking av serumkalsiumnivåer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application